Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + pertuzumab + taxane
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Trastuzumab + pertuzumab + taxane (THP) is a combination chemo-immunotherapy regimen used primarily in the neoadjuvant and first-line metastatic settings for HER2-positive breast cancer. The regimen consists of two HER2-targeted monoclonal antibodies, trastuzumab and pertuzumab, which provide dual HER2 blockade by binding to distinct epitopes (subdomain IV and subdomain II, respectively) of the HER2 receptor. This dual inhibition effectively prevents HER2 dimerization and downstream signaling while promoting antibody-dependent cellular cytotoxicity (ADCC). The taxane component (typically docetaxel, paclitaxel, or nab-paclitaxel) acts as a cytotoxic chemotherapy agent by binding to tubulin and stabilizing microtubules, leading to cell cycle arrest and apoptosis. The combination is currently being evaluated in trials such as neoDIRHP to determine if the number of chemotherapy cycles can be safely de-escalated in intermediate-risk patients.
- Other names
- trastuzumab + pertuzumab + docetaxeltrastuzumab + pertuzumab + paclitaxeltrastuzumab + pertuzumab + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + pertuzumab + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + pertuzumab + taxane.